Company profile · federal money
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (UEI N3F9MH7E6HD6) received $279.40M in federal obligations in FY2026 so far (Defense contracts arrive about 90 days late) in contracts and other awards, the most from Department of Health and Human Services ($279.40M) and mostly under NAICS 541711 (Research and Development in Biotechnology). It ranks #260 among federal contractors that year. Its largest award, HHSO100201700016C, was $280.50M from Department of Health and Human Services.
Key facts · data as of Oct 21, 2026
- Federal obligations, FY2026 so far
- $279.40M
- Rank among federal contractors
- #260
- Largest customer
- Department of Health and Human Services ($279.40M)
- Main industry
- NAICS 541711, Research and Development in Biotechnology
Source: USAspending.gov prime awards (obligations: money committed, not outlays), data as of Oct 21, 2026.
Cite this page: SpendQuery, Regeneron Pharmaceuticals, Inc. federal contracts and awards, data as of Oct 21, 2026, https://spendquery.com/company?key=N3F9MH7E6HD6
Largest customers: Department of Health and Human Services $279.40M
By fiscal year: FY2023 $326.48M · FY2024 -$1.44M · FY2025 -$331.71M · FY2026 $279.40M
Industries (NAICS): Research and Development in Biotechnology $279.40M
Where the work is done: New York $279.40M
Largest awards in FY2026:
- HHSO100201700016C $280.50M from Department of Health and Human Services: Inmazeb Ebola Therapeutics
Data through 2026-10-21; source: USAspending.gov.
Gathering everything on record…
From public government records, which may contain errors. Check the official source before relying on a number. Not financial, legal or investment advice. Terms · About the data